Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican for Prevention of Chronic GVHD and Pulmonary Complications After SCT
NCT01509560Phase 2Completed
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- Nov 2011
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in graft-versus-host disease (GVHD), Pulmonary complication, sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie. Started Nov 2011; status: completed.
02
Drugs
everolimus
03
Conditions
graft-versus-host disease (GVHD)Pulmonary complication
Beyond the preview
Go deeper on NCT01509560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01509560.